Wednesday, 18 November 2026NewsWorldBusinessTech
Latest

White House Pulls FDA Nominee Overton After GOP Support Erodes

The White House withdrew Dr. Heidi Overton’s nomination to lead the Food and Drug Administration on Tuesday night, hours before a Senate committee vote where Republican support had eroded over her positions on vaccines, abortion and vaping.

President Donald Trump nominated Overton, a physician and deputy director of the White House Domestic Policy Council, in August to succeed Dr. Marty Makary, who resigned in May after clashes with the White House over fruit-flavored vape authorizations. The Senate Health, Education, Labor and Pensions Committee was scheduled to vote Wednesday. Overton needed all 12 Republicans on the 21-member panel to advance; Democrats hold the other 11 seats.

Republican opposition centered on three issues

The committee chair and a physician, Sen. Bill Cassidy, R-La., had called Overton’s support for Trump’s plan to break up combination vaccines — including the measles, mumps and rubella shot — “almost disqualifying”. At her September confirmation hearing, Cassidy pressed her on whether she would push back against Trump and Health Secretary Robert F. Kennedy Jr., a longtime vaccine critic. Overton testified that the MMR vaccine is safe and effective.

Democrats and some Republicans also questioned Overton’s record on abortion. In a 2023 policy brief, she criticized expanded access to abortion pills while working at the conservative America First Policy Institute.

At her hearing, she declined to say whether the abortion drug mifepristone is safe and effective, despite decades of FDA approval and peer-reviewed evidence. Sen. Patty Murray of Washington said Overton “would not say what the science has said for years now: that the abortion pill is safe and effective”.

Vaping policy drew scrutiny after reports that Overton worked to relax standards on fruit-flavored vapes. Calley Means alleged on a podcast that Overton advanced vaping industry interests and worked with the Justice Department to construct a legal argument for supporting liability protections for pesticide companies.

Cassidy claims votes existed; White House references vote count

After the withdrawal, Cassidy posted on X that he believed Overton “would have had the votes to pass out of committee and pass the full Senate”. He wrote that anti-abortion senators had sought final assurances from the administration on “life issues” and “the Administration withdrew Dr. Overton rather than make such commitments”. A White House official told CNN the decision came after officials saw skepticism from multiple Senate Republicans.

Sen. Susan Collins of Maine, a Republican who supports abortion rights, had not committed to voting for Overton. She lost her reelection bid earlier this month. Sen. Josh Hawley, R-Mo., had also withheld support, saying he had further questions about the FDA’s mifepristone safety review.

FDA remains without a permanent leader

The agency has been led since May by acting commissioner Kyle Diamantas, an attorney and friend of Donald Trump Jr. It was not immediately clear when, or if, the White House might put forward another FDA nominee. Republicans control the Senate only until January, when Democrats take the majority.

White House Pulls FDA Nominee Overton After GOP Support Erodes
Photo: CNN

Reproductive rights groups celebrate withdrawal

The Reproductive Freedom Alliance, a coalition of two dozen governors, had urged the Senate to halt consideration of Overton’s nomination until the new Congress takes office.

“Earlier this month, voters elected candidates who champion reproductive freedom up and down the ballot, yet the current Senate is moving to fast-track a nominee with a long record of working to restrict abortion access”, the alliance said. Mini Timmaraju, president and CEO of Reproductive Freedom for All, called Overton “a serious threat to the future of medication abortion access”.

“Confirmation is not a coronation”, said Erik Baptist, senior vice president for legal strategy at SBA Pro-Life America. “It is a time to vet nominees and seek commitments before they take office.” The FDA has promised a report on its mifepristone safety review by March.